MultiCell Technologies’ discovery platform is focused on approaches to yield innovative targets and therapeutic strategies, and is based on patented technologies which:

  • Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
  • Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
  • Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.

Our therapeutic development platform has several competitive advantages:

  • Unlike other immune modulating compounds, our novel synthetic double-stranded RNA (dsRNA) can specifically control the immune response through Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or act directly on cancer cells, affording it the potential for use in a broader spectrum of therapeutic applications in oncology and beyond. This concept has yielded two investigational agents: (i) MCT-465 a high molecular weight dsRNA immune enhancing agent for the treatment of cancer; and (ii) MCT-485, a low molecular weight dsRNA anti-tumor cytotoxic agent for the treatment of certain cancers.
  • Our therapeutic antibody technology, Epitope-based T-cell Immunotherapy, can more effectively deliver epitope peptides to the immune system than traditional methods. Coupling our synthetic dsRNA platform technology with our therapeutic antibody technology, maximizes the potential of disease-associated epitope peptides, creating more effective anticancer therapeutics. MCT-475 as an investigational therapeutic antibody agent used in conjunction with MCT-465 for the treatment of various cancers such as breast carcinoma.
  • The ability to isolate and characterize normal stem cells from liver, and potentially isolate and characterize cancer stem cells from liver tumor cells, as discovery tools to support identification of novel therapeutic targets for the treatment of primary hepatocellular carcinoma.


Therapeutic Candidate


Discovery Optimization

Preclinical Development

Phase 1

Phase 2

Phase 3